-
EP3976193
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3976193
| EP3976193 - DOSING OF BISPECIFIC T CELL ENGAGER [Right-click to bookmark this link] | Status | The application has been withdrawn Status updated on 26.05.2023 Database last updated on 16.07.2024 | |
| Former | Request for examination was made Status updated on 04.03.2022 | ||
| Former | The international publication has been made Status updated on 05.12.2020 | ||
| Former | unknown Status updated on 04.08.2020 | Most recent event Tooltip | 26.05.2023 | Withdrawal of application | published on 28.06.2023 [2023/26] | Applicant(s) | For all designated states Amphivena Therapeutics, Inc. 2 Tower Place, Suite 1000 South San Francisco, CA 94080 / US | [2022/14] | Inventor(s) | 01 /
SMITH, Victoria Two Tower Place Suite 1000 South San Francisco, California 94080 / US | [2022/14] | Representative(s) | HGF HGF Limited 1 City Walk Leeds LS11 9DX / GB | [N/P] |
| Former [2022/14] | Fish & Richardson P.C. Highlight Business Towers Mies-van-der-Rohe-Straße 8 80807 München / DE | Application number, filing date | 20746424.9 | 29.05.2020 | [2022/14] | WO2020US35373 | Priority number, date | US201962853802P | 29.05.2019 Original published format: US 201962853802 P | US201962931742P | 06.11.2019 Original published format: US 201962931742 P | [2022/14] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020243603 | Date: | 03.12.2020 | Language: | EN | [2020/49] | Type: | A1 Application with search report | No.: | EP3976193 | Date: | 06.04.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 03.12.2020 takes the place of the publication of the European patent application. | [2022/14] | Search report(s) | International search report - published on: | EP | 03.12.2020 | Classification | IPC: | A61P35/00, C07K16/28, A61K39/395 | [2022/14] | CPC: |
C07K16/2803 (EP);
C07K16/2809 (EP,US);
A61P35/00 (EP);
A61K2039/505 (EP);
A61K2039/545 (EP,US);
A61K9/0019 (US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/14] | Title | German: | DOSIERUNG EINES BISPEZIFISCHEN T-ZELL-ENGAGERS | [2022/14] | English: | DOSING OF BISPECIFIC T CELL ENGAGER | [2022/14] | French: | DOSAGE D'ACTIVATEUR DE LYMPHOCYTES T BISPÉCIFIQUES | [2022/14] | Entry into regional phase | 29.12.2021 | National basic fee paid | 29.12.2021 | Designation fee(s) paid | 29.12.2021 | Examination fee paid | Examination procedure | 29.12.2021 | Examination requested [2022/14] | 29.12.2021 | Date on which the examining division has become responsible | 14.07.2022 | Amendment by applicant (claims and/or description) | 24.05.2023 | Application withdrawn by applicant [2023/26] | Fees paid | Renewal fee | 13.04.2022 | Renewal fee patent year 03 | 14.03.2023 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [I]WO2016004108 (AMPHIVENA THERAPEUTICS INC [US]) [I] 1-17,20,40-42 * claims 1-30 *; | [X]WO2016196230 (AMPHIVENA THERAPEUTICS INC [US]) [X] 1-17,20,40-42 * paragraph [0144]; claims 43-46; sequences 113,138 *; | [X] - WALTER ROLAND B ED - WALTER ROLAND B, "Investigational CD33-targeted therapeutics for acute myeloid leukemia", EXPERT OPINION ON INVESTIGATIONAL DRUGS,, (20180101), vol. 27, no. 4, doi:10.1080/13543784.2018.1452911, pages 339 - 348, XP002797272 [X] 1,11,17,20,40-42 * page 344, column 1, paragraph 6.2 - column 2 * DOI: http://dx.doi.org/10.1080/13543784.2018.1452911 | [X] - GUY DANIEL G ET AL, "Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia", CURRENT HEMATOLOGIC MALIGNANCY REPORTS, CURRENT SCIENCE INC., PHILADELPHIA, PA, US, vol. 13, no. 6, doi:10.1007/S11899-018-0472-8, ISSN 1558-8211, (20181002), pages 417 - 425, (20181002), XP036658878 [X] 1,11,17,20,40-42 * page 420, column 1, paragraph 2; table 1 * DOI: http://dx.doi.org/10.1007/s11899-018-0472-8 | [I] - U. REUSCH ET AL, "Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia", CLINICAL CANCER RESEARCH, US, (20160517), vol. 22, no. 23, doi:10.1158/1078-0432.CCR-16-0350, ISSN 1078-0432, pages 5829 - 5838, XP055333349 [I] 1-17,20,40-42 * the whole document * DOI: http://dx.doi.org/10.1158/1078-0432.CCR-16-0350 | [T] - JOSEPH E. MAAKARON ET AL, "CD33-Targeted Therapies: Beating the Disease or Beaten to Death?", JOURNAL OF CLINICAL PHARMACOLOGY., US, (20200806), doi:10.1002/jcph.1730, ISSN 0091-2700, XP055732032 [T] * the whole document * DOI: http://dx.doi.org/10.1002/jcph.1730 | by applicant | US9212225 | WO2016196230 |